#statusepilepticus — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #statusepilepticus, aggregated by home.social.
-
Living in a rural area may worsen epilepsy outcomes
People with epilepsy living in rural America were more likely to die in hospital, arrive with severe seizures,…
#NewsBeep #News #Health #AU #Australia #Chronic #Diagnostic #Diagnostics #Epilepsy #Healthcare #Hospital #LifeExpectancy #mortality #Neurology #Seizure #StatusEpilepticus #therapy
https://www.newsbeep.com/au/722974/ -
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region https://www.byteseu.com/1454406/ #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #OSAS #Pharma #RegulatoryApproval #StatusEpilepticus #Viatris
-
https://www.alojapan.com/1392924/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region/ Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #JapanNews #news #OSAS #pharma #RegulatoryApproval #StatusEpilepticus #Viatris Strengthens Viatris’ Presence in Japan With the Addition of Two Innovative Assets Targeting Ar
-
https://www.alojapan.com/1392924/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region/ Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #JapanNews #news #OSAS #pharma #RegulatoryApproval #StatusEpilepticus #Viatris Strengthens Viatris’ Presence in Japan With the Addition of Two Innovative Assets Targeting Ar